Blawg Review has the insane task of hosting both Carnival of the Capitalists and Blawg Review #80 today. Given the problems they had crashing their server after it choked on all the links, I think you should give them the honor of your presence by visiting this week’s Review. Besides learning all about early marijuana […]

There is now a website that pays doctors to post medical observations, including reports on side effects and off label uses. Needless to say, this has raised some eyebrows. Sermo Inc. runs a website, sermo.com, as a password-protected private forum where raw postings by doctors can be viewed, for a fee, by Wall Street investment […]

Conflicts of interest in the pharmaceuticals area have been in the news quite a bit lately. I don’t think that it indicates any new trend or that the world going to hell in a handbasket. I think if you want to know the root of the issue, you need look no further than the bottom […]

With the expiry of patents for the blockbuster molecules looming large, the camps of big pharma giants are in disarray. The brain-storming strategies and policies pertaining to evergreening of these patents may be seen in the days to come. Some of the big names in the game include the likes of Pfizer Inc., Merck & […]

In Apotex v. Pfizer (Sup. Ct. 05-1006), the Supreme Court said that it will not hear a case brought by generic pharmaceutical company Apotex that was trying to have Pfizer’s Zoloft patent invalidated. Zoloft (sertraline hydrochloride) is a selective serotonin reuptake inhibitor (SSRI) used to treat depression. Earlier, Pfizer sent Apotex an unconditional covenant not […]

Patents Drive the Economy A Special Report in the Toledo Blade newspaper points out that Ohio’s economy is closely tied to innovation. Manufacturing job loss doesn’t explain why the economy is lagging in certain states, like Ohio. A study by the Cleveland Federal Reserve Bank concluded that patents per-capita were the source of Ohio’s wealth. […]

The Supreme Court heard oral arguments in a case asking whether companies can sue to invalidate another’s patent even when they don’t face an infringement suit, a case that may affect thousands of drug and biotechnology inventions. The case, MedImmune, Inc. v. Genentech, Inc. et al. (No. 05-608), looks at whether a company must stop […]

The U.S. Patent and Trademark Office (USPTO) announced it will re-examine patents covering embryonic stem cell discoveries made by University of Wisconsin researchers. The patents, US Pat. Nos. 5,843,780, 6,200,806, and 7,029,913, cover all embryonic stem cell research in the U.S. The USPTO could revoke, modify or leave intact the patents but any such action […]